Feeds:
Posts
Comments

Archive for the ‘New tests’ Category

JUNE 21: URO TODAY: The human genome project and high throughput gene expression profiling has recently yielded several promising molecular biomarkers for prostate cancer detection beyond PSA or PSA modifications. READ MORE>

Read Full Post »

JUNE 19: FORBES: Shares of Molecular Insight Pharma Inc rose 29 percent in pre-market trade a day after the bio-pharmaceutical company said its imaging agent, Trofex, had the potential to both detect and treat metastatic prostate cancer. READ MORE>

Read Full Post »

JUNE 19: DRUGS.COM: A new marker for advanced prostate cancer and metastasis, or spread, of the disease has been identified by US researchers. Analysis of prostate tissue from men with localised prostate cancer revealed that the men had significantly decreased levels of a stromal protein called caveolin-1. The researchers also found that the protein was not present in tumour tissue from men with metastatic prostate cancer. READ MORE>

Read Full Post »

JUNE 14: INSCIENCES: Prostate cancer patients and their doctors will have a better way of gauging long-term risks and pinpointing high risk cases with a new prostate cancer risk assessment test developed by a University of California San Francisco team. UCSF says the test proved accurate in predicting bone metastasis, prostate cancer-specific mortality, and all-cause mortality when localised prostate cancer is first diagnosed. The test is known as the UCSF Cancer of the Prostate Risk Assessment, or CAPRA. READ MORE>

Read Full Post »

JUNE 13: URO TODAY: WAVE3 is pivotal in controlling the invasiveness of prostate cancer cells, according to a new study at Cardiff University School of Medicine in the UK .

Wiskott-Aldrich syndrome verprolin-homologous 3 (WAVE3) belongs to Wiskott-Aldrich syndrome family proteins, which, along with other members, play a critical role in the regulation of actin polymerization and cell motility. We investigated the expression pattern and the effects of manipulating endogenous WAVE3 expression in prostate cancer cells.

Further work is needed to assess WAVE3 as a potential marker for predicting tumour aggressiveness. READ MORE>

Read Full Post »

JUNE 12: NEWSDAY: Hope for a better prostate cancer test, potential new uses for a largely discredited lung cancer drug and a warning for breast cancer patients all emerged last week from a meeting of the American Society of Clinical Oncology in Orlando, Florida. READ MORE>

Read Full Post »

JUNE 7: LOS ANGELES TIMES:   An experimental blood test that looks at the activity of six genes linked to prostate tumours could greatly improve the accuracy of PSA testing. READ MORE>

Read Full Post »

JUNE 6: BUSINESSWEEK:  A top Johnson & Johnson researcher says the company will cure, prevent or stifle cancer by producing better-targeted drugs, paired with improved diagnostic tests. J&J has two compounds in late-stage testing for prostate cancer. READ MORE>

Read Full Post »

JUNE 5: EUREK ALERT:  An over-the-counter prostate cancer test kit could be coming to a pharmacy near you, thanks to the collaborative work of a University of Central Florida chemist and M.D. Anderson Cancer Center Orlando researchers. READ MORE>

Read Full Post »

JUNE 5: WEB MD:  A blood test that characterises each prostate tumour by its unique genetic fingerprint may help pinpoint which men actually have prostate cancer, researchers say. READ MORE>

Read Full Post »

« Newer Posts - Older Posts »